FDA places partial hold on Biohaven’s epilepsy drug
Published . Updated .
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
Directly affected
- BHVN Biohaven
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
Source: BioPharma Dive
Price since this story was published: Acadia Healthcare (ACHC)
Since the first closing price after “FDA places partial hold on Biohaven’s epilepsy drug,” Acadia Healthcare (ACHC) is +7.90%. The S&P 500 fund (SPY) is +0.77% over the same days, a +7.13% difference versus the market.
Official trades in Acadia Healthcare (ACHC) around 12 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 17 days after publication, inside 30 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 1 days before publication, inside 30 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 40 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 44 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 44 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 51 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “FDA places partial hold on Biohaven’s epilepsy drug.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
The Taiwan Strait count beside this story
Taiwan Strait has 49 linked stories in the last 7 days and 49 in the last 30 on the page that also carries “FDA places partial hold on Biohaven’s epilepsy drug.” The recent pace is rising.
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 12 Sep 2026 story “FDA places partial hold on Biohaven’s epilepsy drug.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “FDA places partial hold on Biohaven’s epilepsy drug,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 12 Sep 2026 story “FDA places partial hold on Biohaven’s epilepsy drug.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “FDA places partial hold on Biohaven’s epilepsy drug,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “FDA places partial hold on Biohaven’s epilepsy drug,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “FDA places partial hold on Biohaven’s epilepsy drug,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “FDA places partial hold on Biohaven’s epilepsy drug” reaches Acadia Healthcare (ACHC)
On 12 Sep 2026, “FDA places partial hold on Biohaven’s epilepsy drug” is the story that connects Acadia Healthcare (ACHC) to Taiwan Strait.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
How solid “FDA places partial hold on Biohaven’s epilepsy drug” looks
46 out of 100
“FDA places partial hold on Biohaven’s epilepsy drug” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.